Combined Microsatellite Instability, MLH1 Methylation Analysis, and Immunohistochemistry for Lynch Syndrome Screening in Endometrial Cancers From GOG210: An NRG Oncology and Gynecologic Oncology Group Study

Autor: Shamshad Ali, Paul DiSilvestro, Russell J. Broaddus, Louise A. Brinton, Feng Gao, Shashikant Lele, Matthew A. Powell, David G. Mutch, Richard J. Zaino, David E. Cohn, Alexis Chassen, Paul J. Goodfellow, Caroline C. Billingsley, Heather A. Lankes, Colin C. Pritchard, Michael L. Pearl, Nilsa C. Ramirez, Amy P. Schmidt, Lisa M. Landrum, Luke V. Simmons, Floor J. Backes, Melissa A. Geller, Heather Hampel
Rok vydání: 2015
Předmět:
Oncology
Cancer Research
DNA Mismatch Repair
0302 clinical medicine
Early Detection of Cancer
Mismatch Repair Endonuclease PMS2
Adenosine Triphosphatases
Gynecologic Cancer
0303 health sciences
Age Factors
Nuclear Proteins
Gync13
ORIGINAL REPORTS
Middle Aged
Immunohistochemistry
Lynch syndrome
Pedigree
3. Good health
DNA-Binding Proteins
Gene Expression Regulation
Neoplastic

MutS Homolog 2 Protein
Population Surveillance
030220 oncology & carcinogenesis
DNA methylation
Female
Microsatellite Instability
DNA mismatch repair
MutL Protein Homolog 1
Adult
congenital
hereditary
and neonatal diseases and abnormalities

medicine.medical_specialty
Gynecologic oncology
MLH1
03 medical and health sciences
Germline mutation
Predictive Value of Tests
Internal medicine
medicine
Humans
Genetic Testing
neoplasms
Germ-Line Mutation
Adaptor Proteins
Signal Transducing

Aged
030304 developmental biology
business.industry
Endometrial cancer
nutritional and metabolic diseases
Microsatellite instability
DNA Methylation
medicine.disease
Colorectal Neoplasms
Hereditary Nonpolyposis

digestive system diseases
Endometrial Neoplasms
DNA Repair Enzymes
business
Zdroj: Journal of Clinical Oncology
ISSN: 1527-7755
0732-183X
Popis: Purpose The best screening practice for Lynch syndrome (LS) in endometrial cancer (EC) remains unknown. We sought to determine whether tumor microsatellite instability (MSI) typing along with immunohistochemistry (IHC) and MLH1 methylation analysis can help identify women with LS. Patients and Methods ECs from GOG210 patients were assessed for MSI, MLH1 methylation, and mismatch repair (MMR) protein expression. Each tumor was classified as having normal MMR, defective MMR associated with MLH1 methylation, or probable MMR mutation (ie, defective MMR but no methylation). Cancer family history and demographic and clinical features were compared for the three groups. Lynch mutation testing was performed for a subset of women. Results Analysis of 1,002 ECs suggested possible MMR mutation in 11.8% of tumors. The number of patients with a family history suggestive of LS was highest among women whose tumors were classified as probable MMR mutation (P = .001). Lynch mutations were identified in 41% of patient cases classified as probable mutation (21 of 51 tested). One of the MSH6 Lynch mutations was identified in a patient whose tumor had intact MSH6 expression. Age at diagnosis was younger for mutation carriers than noncarriers (54.3 v 62.3 years; P < .01), with five carriers diagnosed at age > 60 years. Conclusion Combined MSI, methylation, and IHC analysis may prove useful in Lynch screening in EC. Twenty-four percent of mutation carriers presented with ECs at age > 60 years, and one carrier had an MSI-positive tumor with no IHC defect. Restricting Lynch testing to women diagnosed at age < 60 years or to women with IHC defects could result in missing a substantial fraction of genetic disease.
Databáze: OpenAIRE